Dr. Autorino will discuss some of the findings of the ROBUUST trial looking at Upper Tract Urothelial Carcinoma.

Episode #72: Details of the ROBUUST Trial

Mary Ann Liebert, Inc. is a leading company in the Scientific, Technical, and Medical knowledge and information industry. We are known for authoritative international publications in cutting-edge basic and translational biomedical research, with expanding scope in engineering, business, environment, and legal publications. These publications play an active and important role in advancing critical research and facilitating collaboration throughout the world in academia, industry, and government, and are also highly respected resources for legislators, policy makers, and educators.

Share Episode #72: Details of the ROBUUST Trial

Sign up to save your podcasts

Episode #72: Details of the ROBUUST Trial

Episode #72: Details of the ROBUUST Trial